Pharmaceutical Technology
OCTOBER 30, 2022
Concept: Massachusetts Institute of Technology (MIT)’s Computer Science and Artificial Intelligence Laboratory (CSAIL) researchers have developed a system called ‘series elastic end effectors’ (SEED) that enable robots to use grabbed tools correctly and successfully. It was developed in partnership with the American Toyota Research Institute (a technology research unit of Toyota).
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 30, 2022
Porous particles of silica made from purified sand could one day play a role in attempts to lose weight. Past clinical trials have already produced promising results, but the actual weight-lowering mechanism behind the potential treatment has been poorly understood. [link] To sift out the key variables, researchers have now tested a range of silica […].
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 30, 2022
Concept: Florida-based startup Undefined Technologies (Undefined) has tested the flight of its electric vertical take-off and landing (eVTOL) ion propulsion drone called Silent Ventus. The eVTOL has the potential to redefine dual-purpose cargo delivery drones. Nature of Disruption: Silent Ventus uses patented technology to produce an ‘ionic wind’ that propels the vehicle in the desired direction by ionizing oxygen and nitrogen molecules in the surrounding air.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 30, 2022
High optimism prevails on the implementation of QR code which would aid faster traceability through the supply chain among Indian pharma. Nakul Pasricha, president, Authentication Solution Providers’ Association (ASPA), noted that a sharp spike was observed in the number of counterfeiting incidents related to pharma and medical products estimated as high as at 47 percent. […].
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
OCTOBER 30, 2022
Concept: Canadian software development startup Minerva Intelligence has launched an AI-powered application programming interface (API) called climate85 API for climate risk data. It offers the ability to measure the effects of climate change on business owners, investors, and portfolio managers. Nature of Disruption: climate85 API comprises comprehensive climate risk datasets which are created using advanced scientific methodologies and are based on a selected group of global climate models and
NPR Health - Shots
OCTOBER 30, 2022
Shanghai Disney Resort, which includes Shanghai Disneyland, shopping and dining facilities, will be closed indefinitely starting on Halloween due to the coronavirus pandemic.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
OCTOBER 30, 2022
Consider limiting your use of “manage” on your resume, opting instead for more powerful, descriptive synonyms. To help, here are 19 powerful keywords for your resume to indicate you're a leader.
Pharmaceutical Technology
OCTOBER 30, 2022
Concept: Robert Bosch (Bosch) has developed a surround sensing and collision warning system for more precise construction vehicle maneuvering. It has also partnered with Bosch Rexroth to deliver the off-highway robotics controller (ORC). The ORC is a potent control module that serves as the brain of the automated machine and offers the ability to support and relieve pressure in challenging use cases.
BioSpace
OCTOBER 30, 2022
Scorpion Therapeutics is on a mission to create a world where many more cancer patients can benefit from precision therapies. Earlier this year, it struck a $75 million alliance with AstraZeneca.
JAMA Internal Medicine
OCTOBER 30, 2022
This cross-sectional study estimates all US Food and Drug Administration anticancer approvals in recent years and evaluates if an association exists between their cost and efficacy.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioSpace
OCTOBER 30, 2022
CytoDyn withdrew its pending Biologics License Application for leronlimab in HIV, citing concerns involving the contract research organization managing its trials.
FDA Law Blog
OCTOBER 30, 2022
By McKenzie E. Cato — On October 21, 2022, FDA published a draft guidance document titled Select Updates for the Breakthrough Devices Program Guidance: Reducing Disparities in Health and Health Care. This draft guidance proposes updates to FDA’s Breakthrough Devices Program, which is outlined in a separate December 2018 guidance document. FDA intends to incorporate these updates into the December 2018 Breakthrough Devices Program guidance after considering public comment.
BioSpace
OCTOBER 30, 2022
The implications of the Inflation Reduction Act of 2022 (IRA) are beginning to show as Alnylam drops the Stargardt indication for vutrisiran and Sanofi's CEO reassures investors.
Drug Patent Watch
OCTOBER 30, 2022
[
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioSpace
OCTOBER 30, 2022
While reporting stellar third-quarter financials, AbbVie announced it was halting development of cedirogant and provided updates on Skyrizi, Rinvoq and Humira.
Drug Patent Watch
OCTOBER 30, 2022
[
BioSpace
OCTOBER 30, 2022
ESSA confirmed that Janssen has stepped away from a prostate cancer collaboration due to “operational recruitment challenges.
Drug Patent Watch
OCTOBER 30, 2022
This chart shows the pharmaceutical companies with the most patents in New Zealand. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical companies have the most drug patents in New Zealand? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioSpace
OCTOBER 30, 2022
Platform technology company Replay, based in San Diego and London, has launched Eudora, a gene therapy company targeting genetic diseases of the retina.
pharmaphorum
OCTOBER 30, 2022
Shares in US biotech Y-mAbs Therapeutics have lost almost a third of their value after FDA advisors unanimously rejected its brain cancer therapy 131I-omburtamab in 16 to 0 vote. The Oncologic Drugs Advisory Committee (ODAC) concluded that Y-mAbs had not provided sufficient evidence that omburtamab was able to improve overall survival in children with neuroblastoma that had spread to the central nervous system or leptomeninges – the thin layers of tissue that cover the brain and spinal cord.
BioSpace
OCTOBER 30, 2022
The FDA's Oncologic Drugs Advisory Committee voted unanimously against approving l-omburtamab for children with a rare form of neuroblastoma, citing complex review issues.
Expert insights. Personalized for you.
246 
Let's personalize your content